Global Blood Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 457

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $5.7B

Global Blood Therapeutics General Information

Description

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Contact Information

Website
www.gbt.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 181 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 181 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Global Blood Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 05-Oct-2022 $5.7B Completed Generating Revenue
10. Debt - General 01-Dec-2019 Completed Generating Revenue
9. 2PO 11-Dec-2018 Completed Generating Revenue
8. Secondary Transaction - Open Market 31-Mar-2018 Completed Generating Revenue
7. 2PO 12-Mar-2018 Completed Generating Revenue
6. Merger/Acquisition 08-Mar-2017 Cancelled Pre-Clinical Trials
5. 2PO 19-Jan-2017 Completed Pre-Clinical Trials
4. 2PO 20-Jun-2016 Completed Pre-Clinical Trials
3. IPO 12-Aug-2015 $120M $218M Completed Pre-Clinical Trials
2. Early Stage VC (Series B) 06-Jan-2015 $48M $97.9M Completed Startup
To view Global Blood Therapeutics’s complete valuation and funding history, request access »

Global Blood Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
To view Global Blood Therapeutics’s complete cap table history, request access »

Global Blood Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel th
Drug Discovery
South San Francisco, CA
457 As of 2021

Rahway, NJ
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Global Blood Therapeutics Competitors (10)

One of Global Blood Therapeutics’s 10 competitors is Merck & Co., a Corporation company based in Rahway, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ
Agenus Formerly VC-backed Lexington, MA
Geron Formerly VC-backed Foster City, CA
Genentech Formerly VC-backed South San Francisco, CA
Bristol-Myers Squibb Corporation Princeton, NJ
You’re viewing 5 of 10 competitors. Get the full list »

Global Blood Therapeutics Patents

Global Blood Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4727555-A1 (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease Pending 13-Jun-2023
US-20260306503-A1 (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease Pending 13-Jun-2023
WO-2024256964-A1 (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease Inactive 13-Jun-2023
AU-2022408097-A1 Methods of administering a modulator of hemoglobin Active 10-Dec-2021
AU-2022408097-B2 Methods of administering a modulator of hemoglobin Active 10-Dec-2021 A61K31/5377
To view Global Blood Therapeutics’s complete patent history, request access »

Global Blood Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Global Blood Therapeutics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aisling Capital Venture Capital Minority
Avoro Capital Venture Capital Minority
Cowen Healthcare Investments Venture Capital Minority
Deerfield Management Venture Capital Minority
Fidelity Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

Global Blood Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

15.64 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Global Blood Therapeutics’s complete esg history, request access »

Global Blood Therapeutics FAQs

  • When was Global Blood Therapeutics founded?

    Global Blood Therapeutics was founded in 2011.

  • Where is Global Blood Therapeutics headquartered?

    Global Blood Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Global Blood Therapeutics?

    Global Blood Therapeutics has 457 total employees.

  • What industry is Global Blood Therapeutics in?

    Global Blood Therapeutics’s primary industry is Drug Discovery.

  • Is Global Blood Therapeutics a private or public company?

    Global Blood Therapeutics is a Private company.

  • What is the current valuation of Global Blood Therapeutics?

    The current valuation of Global Blood Therapeutics is .

  • What is Global Blood Therapeutics’s current revenue?

    The current revenue for Global Blood Therapeutics is .

  • How much funding has Global Blood Therapeutics raised over time?

    Global Blood Therapeutics has raised $1.05B.

  • Who are Global Blood Therapeutics’s investors?

    Aisling Capital, Avoro Capital, Cowen Healthcare Investments, Deerfield Management, and Fidelity are 5 of 11 investors who have invested in Global Blood Therapeutics.

  • Who are Global Blood Therapeutics’s competitors?

    Merck & Co., Agenus, Geron, Genentech, and Bristol-Myers Squibb are some of the 10 competitors of Global Blood Therapeutics.

  • When was Global Blood Therapeutics acquired?

    Global Blood Therapeutics was acquired on 05-Oct-2022.

  • Who acquired Global Blood Therapeutics?

    Global Blood Therapeutics was acquired by Pfizer.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process